Print Page  E-mail Page  RSS  E-mail Alerts  Tearsheet 

Investor Home

Advanced Accelerator Applications (AAA) is an innovative radiopharmaceutical company that develops, produces and commercializes molecular nuclear medicine, or MNM, products.

AAA is a European leader in the production and commercialization of molecular nuclear diagnostic radiopharmaceuticals for PET and SPECT. These radiopharmaceuticals are mainly used for diagnosis in clinical oncology, cardiology and neurology.... more >


September 26, 2016 - Special Meeting of Stockholders

Materials

Latest Newsmore >
09/22/16
EMA Prematurely Announced Opinion on SomaKit TOC® Kit Application
SAINT-GENIS-POUILLY, France, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, announced today that the European Medicines Agency (EMA) prematurely notified the public and the company of its opinion on the Marketing Authorization Application for SomaKit TOC®, a kit for radiopharmaceutical preparation of gallium (Ga 68) edotreotide solution for injection, for Positron Emiss... 
09/20/16
Advanced Accelerator Applications Announces Revised EMA Review Timeline for Lutathera®
SAINT-GENIS-POUILLY, France, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in Molecular Nuclear Medicine (MNM), today announced that the Accelerated Assessment timeline for the European Medicines Agency (EMA) review of the Marketing Authorization Application (MAA) for Lutathera®, a Lu-177-labeled somatostatin analogue peptide currently under development for the treatment of neuroendocrine tumors (NE... 
09/16/16
Advanced Accelerator Applications Announces Positive EMA Opinion on Application for SomaKit TOC Kit for Radiopharmaceutical Preparation of Gallium (Ga 68) Edotreotide for Gastroenteropancreatic Neuroendocrine Tumor Detection
SAINT-GENIS-POUILLY, France, Sept. 16, 2016 (GLOBE NEWSWIRE) -- Advanced Accelerator Applications S.A. (NASDAQ:AAAP) (“AAA” or “the Company”), an international specialist in molecular nuclear medicine, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Marketing Authorization Application for SomaKit TOC 40µg, a kit for radiopharmaceutical preparation of gallium (Ga 68) edotreotide solution for injection, for Positron Emission Tomography (PET) imaging ... 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources